Antiplatelet reconciliation
Ticagrelor and aspirin: maintenance instructions are not loading instructions
The aspirin amount on a ticagrelor discharge list needs a purpose and duration check. A loading dose is not a reason to retain a higher daily maintenance dose, and newer single-antiplatelet options do not authorize an unreviewed change.
Sources checked October 13, 2026. Independent educational content, not NABP exam questions or individual treatment advice.
Separate the initial event from the daily plan
A case may show aspirin 325 mg given during an acute event and then copied onto a daily maintenance list with ticagrelor. The label's maintenance instruction is 75 to 100 mg daily when aspirin is used with Brilinta. Loading and maintenance are different stages.
Ask whether the higher amount is a one-time load or an ongoing order before declaring the entire regimen wrong. The important error is retaining an incompatible maintenance instruction, not assuming every mention of 325 mg refers to the same use.
Read the current label exception accurately
The cited label says that in patients who have undergone PCI, single antiplatelet therapy with Brilinta may be considered based on evolving thrombotic versus bleeding risk. This is a clinical choice, not a universal instruction that every patient should omit aspirin.
A verified specialist plan may therefore differ from a simple combination-therapy template. Recover that plan and its timing. Do not independently add aspirin because an old discharge template always included it, or remove it because a newer option exists.
Check interactions and symptoms as separate issues
The label advises avoiding strong CYP3A inhibitors and inducers. Clarithromycin is listed among the strong inhibitors. That check matters even if aspirin is correctly selected. Dose reconciliation cannot be limited to the two antiplatelets.
Dyspnea is a recognized adverse effect, but a report of breathlessness still needs clinical assessment. It should not be assumed harmless or used as a reason for unsupervised discontinuation. Bleeding symptoms and other contraindications also need review.
Avoid an unplanned treatment gap
The label warns that stopping Brilinta increases cardiovascular event risk. An identified maintenance error should lead to a prompt coordinated correction, not casual advice to stop the entire antiplatelet regimen while waiting for an answer.
The worked example tests the aspirin maintenance range and an interaction. It does not select the duration of dual therapy or adjudicate an individual's thrombotic and bleeding risks. Those decisions depend on the treating team's plan.
A worked case
A post-PCI discharge draft lists Brilinta and aspirin 325 mg every day, carried over from the acute-event chart. A new clarithromycin order is also present. What two issues should the pharmacist verify?
- Determine whether 325 mg is truly the maintenance order rather than a one-time load.
- The labeled combination maintenance range is 75 to 100 mg aspirin daily.
- Clarithromycin is a listed strong CYP3A inhibitor to avoid with Brilinta.
Answer: Clarify the aspirin maintenance plan and the interacting antibiotic. Do not create an unsupervised antiplatelet interruption.
Try it before reading the answer
Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.
1. Is a loading dose automatically the correct daily maintenance dose?
No.
2. What aspirin maintenance range does the cited combination instruction give?
75 to 100 mg daily.
3. Does the post-PCI single-therapy option mean everyone should stop aspirin?
No. It requires assessment of the evolving thrombotic and bleeding risks.
Continue learning
Put the topic into a study planSources and scope
Source dates and limits matter. Follow the current official source for clinical or regulatory decisions. Examples are simplified teaching cases, not prescribing, diagnostic or compounding instructions. Check the full current guidance and individual clinical context.